Research Article
BibTex RIS Cite

Over tümörlerinin ayırıcı tanısında sistemik inflamatuar belirteçlerin rolü

Year 2023, Volume: 20 Issue: 2, 1769 - 1772, 03.07.2023
https://doi.org/10.38136/jgon.1278471

Abstract

Amaç: Çalışmamızda preoperatif inflamatuar kan parametrelerinin benign seröz kistadenom, seröz borderline ovarian tümör (BOT) ve high grade over karsinomu (HGSOC) ayırıcı tanısındaki yerini analiz etmek amaçlandı.
Gereçler ve Yöntemler: Ovaryan tümöre sahip 370 hasta retrospektif olarak 3 grup olarakdeğerlendirldi. Hastalar benign seröz kistadenom, seröz BOT ve HGSOC olarak gruplandırıldı. Preoperatif kan inflamatuar parametreleri: Hemoglobin (Hb), kırmızı hücre dağılım genişliği (RDW), Hb/RDW, Nötrofil / Lenfosit(N/L) ve Platelet/Lenfosit (P/L) oranları analiz edildi.
Bulgular: P/L and N/L benign serös kist adenoma veya seröz BOT'ı da HGSOC 'ye göre önemli anlamlı derecede düşük olduğu bulundu (p<0.001 and p<0.001). Benign seröz kistadenom, seröz BOT ve HGSOC ile karşılaştırıldığında daha düşük median değere sahip olduğu saptandı (p<0.001).
Hb/RDW oranı HGSOC'lu hastalarda istatiksel olarak anlamlı olarak en düşük, benign seröz kistadenomlu hastalarda anlamlı olarak en yüksekti (p<0.001).
Sonuç: Preoperatif Hb/RDW, benign seröz kistadenom, seröz BOT ve HGSOC'nin ayırt edilmesinde belirleyici olarak kullanılabilir olduğunu düşünmekteyiz. N/L ve P/L, benign seröz kistadenom ve seröz BOT'ı HGSOC'den ayırt etmek için kullanılabilir .

References

  • 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, vd. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwi- de for 36 Cancers in 185 Countries. CA Cancer J Clin. Mayıs 2021;71(3):209-49. 2. Atallah GA, Abd. Aziz NH, Teik CK, Shafiee MN, Kam- pan NC. New Predictive Biomarkers for Ovarian Cancer. Diag- nostics. 07 Mart 2021;11(3):465. 3. Yun TH, Jeong YY, Lee SJ, Choi YS, Ryu JM. Neut- rophil–Lymphocyte and Platelet–Lymphocyte Ratios in Preope- rative Differential Diagnosis of Benign, Borderline, and Malig- nant Ovarian Tumors. JCM. 01 Mart 2022;11(5):1355. 4. Diakos CI, Charles KA, McMillan DC, Clarke SJ. Can- cer-related inflammation and treatment effectiveness. The Lan- cet Oncology. Ekim 2014;15(11):e493-503.

The Role of Systemic Inflammatory Response Markers in Differential Diagnosis of Ovarian Tumors

Year 2023, Volume: 20 Issue: 2, 1769 - 1772, 03.07.2023
https://doi.org/10.38136/jgon.1278471

Abstract

Aim: The aim of this study is evaluating the predictive value of preoperative inflammatory blood parameters for differential of serous cystadenoma, serous borderline ovarian tumor (BOT) and high-grade serous ovarian (HGSOC) carcinoma.
Materials and Method: In this single-center study, we retrospectively enrolled 370 patients with ovarian tumors were divided into three groups. The groups were classified as serous cystadenoma, serous BOT and HGSOC. The potential association of preoperative hemoglobin (Hb), red cell distribution width (RDW), Hb/RDW ratio, ratio of neutrophils to lymphocytes (N/L) and ratio of platelets to lymphocytes (P/L) were analyzed.
Results: P/L and N/L were significantly lower in benign serous cystadenoma or serous BOT than HGSOC (p<0.001 and p<0.001). Benign serous cystadenoma was significantly associated with lower median RDW compared to serous BOT and HGSOC (p<0.001). Hb/RDW ratio was significantly lowest in patients with HGSOC and significantly highest in patients with benign serous cystadenoma (p<0.001).
Conclusion: Preoperative Hb/RDW can be used as predictor for discrimination of benign serous cystadenoma, serous BOT and HGSOC. N/L and P/L may be considered to distinguish the benign serous cystadenoma and serous BOT from HGSOC.

References

  • 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, vd. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwi- de for 36 Cancers in 185 Countries. CA Cancer J Clin. Mayıs 2021;71(3):209-49. 2. Atallah GA, Abd. Aziz NH, Teik CK, Shafiee MN, Kam- pan NC. New Predictive Biomarkers for Ovarian Cancer. Diag- nostics. 07 Mart 2021;11(3):465. 3. Yun TH, Jeong YY, Lee SJ, Choi YS, Ryu JM. Neut- rophil–Lymphocyte and Platelet–Lymphocyte Ratios in Preope- rative Differential Diagnosis of Benign, Borderline, and Malig- nant Ovarian Tumors. JCM. 01 Mart 2022;11(5):1355. 4. Diakos CI, Charles KA, McMillan DC, Clarke SJ. Can- cer-related inflammation and treatment effectiveness. The Lan- cet Oncology. Ekim 2014;15(11):e493-503.
There are 1 citations in total.

Details

Primary Language English
Subjects Obstetrics and Gynaecology
Journal Section Research Articles
Authors

Sevgi Serdar 0000-0002-5556-6154

Günsu Kimyon Cömert 0000-0003-0178-4196

Özgün Ceylan 0000-0001-9975-2058

İrem Kar 0000-0002-1747-4312

Hakan Raşit Yalçın 0000-0002-9027-1351

Taner Turan 0000-0001-8120-1143

Publication Date July 3, 2023
Submission Date April 6, 2023
Acceptance Date May 9, 2023
Published in Issue Year 2023 Volume: 20 Issue: 2

Cite

Vancouver Serdar S, Kimyon Cömert G, Ceylan Ö, Kar İ, Yalçın HR, Turan T. The Role of Systemic Inflammatory Response Markers in Differential Diagnosis of Ovarian Tumors. JGON. 2023;20(2):1769-72.